期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 123, 期 3, 页码 798-806出版社
WILEY
DOI: 10.1002/jso.26416
关键词
cancer; immunotherapy; solid tumors; tumor immunology
资金
- NCATS NIH HHS [UL1 TR002378, TL1 TR002382] Funding Source: Medline
- NCI NIH HHS [F30 CA243307] Funding Source: Medline
This article discusses the importance of immunotherapy in cancer treatment and presents successful cases of PD-1 and CTLA-4 blockade therapy, as well as biomarkers of therapeutic response. Additionally, it also examines novel targets in Phase III clinical trials and innovations aimed at improving outcomes in therapy-resistant solid tumors.
While surgical resection, local and cytotoxic therapies have long formed the basis of cancer care, immunotherapy now plays a key role in supplementing and even replacing these agents in the first line. Here we review the early success of programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 blockade and discuss biomarkers of therapeutic response. We next highlight a select group of novel targets in Phase III trials both as monotherapies and in combination with PD-1 inhibitors. Finally, we discuss innovations which seek to improve outcomes in therapy-resistant solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据